Frontlight ResearchEarly access
Not yet taking people in SpainPhase 4
Studying how an SGLT2 inhibitor works in heart failure with preserved ejection fraction
Tests how an SGLT2 inhibitor acts in adults with heart failure with preserved ejection fraction.
Key facts
- Who runs it
- Fundación para la Innovación en Biomedicina
- Where
- Madrid, SpainSee the site
- Registry title
- Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Started
- 1 Jun 2023
- Planned end
- 1 Jun 2026
- Type of study
- Interventional
- Record updated
- 31 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure with preserved ejection fraction (LVEF 50% or more) who are clinically stable and are about to start an SGLT2 inhibitor medicine for the first time.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Heart failure with LVEF ≥ 50% and signs of diastolic dysfunction on heart ultrasound. A hospital stay or intravenous diuretic treatment in the previous 6 months. Stable for more than 1 month. People with or without type 2 diabetes can join.
- Earlier treatment
- Must not have had SGLT2 inhibitor treatment before or now. Must have a clinical indication to start a new SGLT2 inhibitor. Must have a clinical indication for cardiac catheterization.
Main reasons for not taking part
- Taking part in another clinical trial in the last 30 days
- Pregnant or breastfeeding women
- Significant coronary artery disease
- Aortic or mitral valve disease of moderate degree or worse
- Stroke in the last 12 months
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adults of both genders ≥ 18 years
- LVEF ≥ 50%
- Diagnosis of HFpEF according to clinical criteria, with a history of hospitalization or the need for intravenous diuretic treatment in the previous 6 months, along with evidence of diastolic dysfunction based on echocardiographic criteria
- Patients with or without Type II Diabetes Mellitus
- Clinically stable condition (> 1 month after hospitalization for HF decompensation or since the last dose of intravenous diuretic treatment)
- Clinical indication for cardiac catheterization
- Clinical indication to receive de novo treatment with SGLT2 inhibitors
- Signed informed consent
Who cannot take part
- Participation in another clinical trial within 30 days prior to the start of the current study
- Prior or current treatment with SGLT2 inhibitors
- Stroke within 12 months prior to inclusion
- Significant coronary artery disease
- Aortic or mitral valvular disease ≥ moderate
- Respiratory impairment or the need for home oxygen therapy
- Contraindications for dapagliflozin treatment according to the product label (hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; moderate-to-severe renal insufficiency - CrCl < 60 ml/min or eGFR < 60 ml/min/1.73 m² -; severe hepatic insufficiency)
- Pregnant or breastfeeding women
- Life expectancy of less than 2 years due to any cause
Where in Spain
- Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
About the trial
What the trial wants to find out
To identify the underlying the biological and biomechanical mechanisms responsible for the cardiovascular benefit demonstrated by iSGLT2 in patients with ICFEP.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction
- Plain-language title
- Studying how an SGLT2 inhibitor works in heart failure with preserved ejection fractionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 31 January 2025